药物相关性颌骨坏死研究进展  

Research progress on medication-related osteonecrosis of the jaw

作　　者：高婷婷 鲍永接 吕晓燕 陈贤 刘杨 徐逸磊 卢焕友 Gao Tingting;Bao Yongjie;Lv Xiaoyan;Chen Xian;Liu Yang;Xu Yilei;Lu Huanyou(An Yu Oral Medical Group of Chongqing Clinic,Chongqing 400000,China)

机构地区：[1]安玉口腔医疗集团重庆门诊部,400000

出　　处：《中国口腔种植学杂志》2024年第5期492-497,共6页Chinese Journal of Oral Implantology

摘　　要：在应用抗骨吸收药物,如双膦酸盐和地舒单抗,以及血管生成抑制剂的患者群体中,进行相关口腔疾病的治疗可能会诱发药物相关性颌骨坏死(medication-related osteonecrosis of the jaw,MRONJ)。然而,MRONJ的确切机制尚不清楚,尽管大量研究已经创建了临床治疗数据库,但明确的治疗策略尚未制定。本研究通过文献回顾,对MRONJ的定义、病因、分期、危险因素、治疗和预防进行了相关讨论,为口腔临床工作提供参考。Medication-related osteonecrosis of the jaw(MRONJ)may be induced during the treatment of oral diseases in patients receiving anti-resorptive drugs such as bisphosphonates and denosumab,as well as angiogenesis inhibitors.However,the exact mechanism of MRONJ remains unclear,and although numerous studies have established clinical treatment databases,definitive treatment strategies have yet to be developed.Through a review of the literature,this study discusses the definition,etiology,staging,risk factors,treatment and prevention of MRONJ,providing a reference for clinical practice in oral healthcare.

关 键 词：双膦酸盐相关性颌骨坏死 药物相关性颌骨坏死 双膦酸盐 地舒单抗 

分 类 号：R782[医药卫生—口腔医学]